Intellia reports a grade 4 liver enzyme elevation in a Nex-Z trial patient; no hospitalization is required, and enrollment ...

Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation.

Intellia Therapeutics shares fell 25% amid safety concerns in Phase 3 trials. Check out if today's selloff in NTLA stock is a ...

Intellia has leveraged its expertise in Crispr/Cas9 gene editing to advance a pipeline of in vivo and ex vivo therapies for diseases with high unmet medical needs. We believe Intellia's proprietary ...

Upon potential approval, the company plans to launch NTLA-2002 in 2027 in the United States. In October 2024, NTLA initiated the HAELO study on NTLA-2002 for treating HAE.

Intellia has been developing another pipeline candidate, NTLA-2002, for the treatment of hereditary angioedema (“HAE”). The company dosed the first patient in the pivotal phase III HAELO study ...

CRSP aims to extend its gene-editing lead with in vivo candidates after Casgevy's ex vivo breakthrough success.

and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to ...

Management reaffirmed its goal to file a BLA for NTLA-2002 for HAE in 2026. This submission will depend on data from the ongoing Phase 3 HAELO study, expected to complete enrollment by Q3 2025.

The CRISPR specialist said that a single 50mg infusion of NTLA-2002 – which switches off a gene involved in the potentially life-threatening inflammatory attacks that characterise HAE ...